What is chronic myeloid leukemia?
Chronic myeloid leukemia (also called chronic myelogenous leukemia or CML) is a form of leukemia (blood cancer) that develops in the bone marrow, the soft, spongy center of long bones. CML affects a subtype of white blood cell called a “myeloblast.” Normal myoblasts grow, divide and mature into white blood cells capable of fighting infections. This process is controlled by the body through complex signaling networks. In a child with CML, the bone marrow makes abnormal myeloblasts that don’t respond to these normal signals and therefore produce large amounts of abnormal white blood cells in an uncontrolled manner. These abnormal cells do not fight infections, and instead spill into the blood in large numbers, causing a variety of serious problems.
CML is very rare in children. Approximately 150 children in the U.S. are diagnosed with CML each year.
How we care for CML
Children and adolescents with leukemia are treated at Dana-Farber/Boston Children's through our Hematologic Malignancy Center's Leukemia Program. Dana-Farber/Boston Children’s has played a key role in refining treatment for childhood leukemia, and we continue to be a world leader in leukemia clinical trials. The Leukemia Program also offers families the chance to have their child's leukemia cells molecularly profiled, which may help identify opportunities for targeted treatment.
Find in-depth details on CML on the Dana-Farber Cancer Institute website, including details on CML diagnosis, treatment and more.